Varenicline as a DREADD Actuator Elicits Off-Target Effects on Somatosensation, Locomotion, and Anxiety-Related Behaviors in Rats.
As a new-generation chemogenetic actuator in designed receptors exclusively activated by designer drugs (DREADD) systems, varenicline (VAR) is gaining popularity in studies involving both nonhuman primates and rodents. However, its acute off-target effects on somatosensation and anxiety-related behaviors in rodents remain largely uncharacterized. Using classical behavioral paradigms─including evoked itch-scratching, noxious thermal pain testing, open field, and elevated plus maze assays─we demonstrate that intraperitoneal administration of standard VAR doses modulates itch/pain sensation, basal locomotor activity, and anxiety-related emotional behaviors in Sprague-Dawley (SD) rats. Key findings include the following: high-dose VAR (0.2 mg/kg) significantly increased 5-HT-induced itch-scratching behavior; both low- (0.1 mg/kg) and high-dose VAR elevated sensitivity to noxious thermal stimuli; high-dose VAR enhanced basal locomotor activity in OFT, while low-dose VAR induced anxiety-related phenotypes in EPM. Fiber photometry further revealed that both doses of VAR enhanced neuronal activity in the prelimbic cortex (PrL) and central amygdala (CeA). These results indicate that VAR, at doses commonly employed for DREADD activation, elicits off-target effects on somatosensation, spontaneous locomotion, and anxiety-related emotional behaviors. The underlying mechanisms may involve VAR-induced neuronal hyperactivation in the PrL and CeA, potentially mediated by ligand/metabolite interactions with endogenous brain receptors. By identifying dose-dependent off-target actions of VAR, a next-generation chemogenetic ligand, this study underscores the necessity of including ligand-only controls in DREADD experiments and urges cautious interpretation of behavioral outcomes attributed to VAR-mediated chemogenetic manipulations.
- Research Article
1
- 10.1016/j.brainresbull.2025.111474
- Sep 1, 2025
- Brain research bulletin
Off-targets effects of CNO on somatosensory and anxiety-related behaviors in rats.
- Research Article
15
- 10.1016/j.yhbeh.2023.105363
- Apr 21, 2023
- Hormones and behavior
No detectable changes in anxiety-related and locomotor behaviors in adult ovariectomized female rats exposed to estradiol, the ERβ agonist DPN or the ERα agonist PPT
- Research Article
153
- 10.1523/jneurosci.0705-18.2018
- May 29, 2018
- The Journal of Neuroscience
Both the amygdala and the bed nucleus of the stria terminalis (BNST) have been implicated in maladaptive anxiety characteristics of anxiety disorders. However, the underlying circuit and cellular mechanisms have remained elusive. Here we show that mice with Erbb4 gene deficiency in somatostatin-expressing (SOM+) neurons exhibit heightened anxiety as measured in the elevated plus maze test and the open field test, two assays commonly used to assess anxiety-related behaviors in rodents. Using a combination of electrophysiological, molecular, genetic, and pharmacological techniques, we demonstrate that the abnormal anxiety in the mutant mice is caused by enhanced excitatory synaptic inputs onto SOM+ neurons in the central amygdala (CeA), and the resulting reduction in inhibition onto downstream SOM+ neurons in the BNST. Notably, our results indicate that an increase in dynorphin signaling in SOM+ CeA neurons mediates the paradoxical reduction in inhibition onto SOM+ BNST neurons, and that the consequent enhanced activity of SOM+ BNST neurons is both necessary for and sufficient to drive the elevated anxiety. Finally, we show that the elevated anxiety and the associated synaptic dysfunctions and increased dynorphin signaling in the CeA-BNST circuit of the Erbb4 mutant mice can be recapitulated by stress in wild-type mice. Together, our results unravel previously unknown circuit and cellular processes in the central extended amygdala that can cause maladaptive anxiety.SIGNIFICANCE STATEMENT The central extended amygdala has been implicated in anxiety-related behaviors, but the underlying mechanisms are unclear. Here we found that somatostatin-expressing neurons in the central amygdala (CeA) controls anxiety through modulation of the stria terminalis, a process that is mediated by an increase in dynorphin signaling in the CeA. Our results reveal circuit and cellular dysfunctions that may account for maladaptive anxiety.
- Research Article
17
- 10.1016/j.physbeh.2023.114343
- Sep 9, 2023
- Physiology & behavior
Diazepam effects on anxiety-related defensive behavior of male and female high and low open‐field activity inbred mouse strains
- Research Article
11
- 10.1016/j.neuroscience.2018.08.007
- Aug 18, 2018
- Neuroscience
Involvement of Serotonergic and Relaxin-3 Neuropeptide Systems in the Expression of Anxiety-like Behavior
- Research Article
125
- 10.1016/j.neuroscience.2011.11.054
- Dec 8, 2011
- Neuroscience
Aerobic exercise prevents age-dependent cognitive decline and reduces anxiety-related behaviors in middle-aged and old rats
- Research Article
36
- 10.1016/j.physbeh.2009.12.006
- Dec 13, 2009
- Physiology & Behavior
Medial amygdala lesions differentially influence stress responsivity and sensorimotor gating in rats
- Research Article
96
- 10.1016/s0031-9384(98)00119-x
- Jun 1, 1998
- Physiology & Behavior
Vasopressin administration modulates anxiety-related behavior in rats
- Research Article
20
- 10.1272/jnms.78.286
- Jan 1, 2011
- Journal of Nippon Medical School
Corticotropin-releasing factor (CRF) in the medial prefrontal cortex (mPFC) is suggested to play an important role in mediating fear, anxiety, and depression. The results of the studies of the actions of CRF in the mPFC regarding anxiety-related behavior, however, seem contradictory. In one study, microinjection of CRF into the mPFC produced an increase in anxiety-related behavior on the elevated plus maze, whereas in another study CRF produced an anxiolytic-like effect. To test whether the different doses of CRF used in these experiments are responsible for the differing results, we examined the dose-dependent effects of CRF (0.015, 0.05, 0.15, 0.5, and 1.0 µg/0.5 µL/site) microinjected into the bilateral mPFC of male Wistar rats on anxiety-related behavior in the elevated plus maze. We found that microinjection of 0.05 µg CRF significantly decreased the number of open-arm entries, whereas 1.0 µg CRF significantly increased the time spent on the open arms. The results indicate that CRF has effects opposing anxiety-related behavior in the elevated plus maze: anxiety-related behavior at a lower dose and an anxiolytic-like effect at a higher dose.
- Research Article
37
- 10.1097/00008877-200512000-00007
- Dec 1, 2005
- Behavioural Pharmacology
Reports indicate that histamine and histaminergic agents can change anxiety-related behaviours in both animals and humans. The amygdala is an important brain site in the modulation of fear or anxiety. In the present study, we investigated the effects of intracentral amygdala microinjection of histaminergic agents on anxiety-related behaviours in rats, using the elevated plus-maze test of anxiety. Intracentral amygdala administration of histamine (0.01-0.5 microg/0.5 microl bilateral) decreased %open armtime and % open arm entries, but not locomotor activity, showing an anxiogenic response. Intracentral amygdala microinjection of pyrilamine (H1 receptor antagonist) and ranitidine (H2 receptor antagonist) (both at 1-20 microg/0.5 microl bilateral) did not change anxiety-related parameters in our experiments. In another series of experiments, histamine (0.5 microg/0.5 microl bilateral) was coadministrated with pyrilamine and ranitidine (both at 1-20 mg/0.5 microl bilateral). The results showed that pyrilamine but not ranitidine could significantly reverse the anxiogenic effect of histamine at doses of 10 and 20 microg/0.5 microl bilateral. The results suggest that histamine may modulate anxiety via H1 but not H2 receptors in the rat central amygdala.
- Research Article
774
- 10.1016/j.neuron.2009.12.002
- Jan 1, 2010
- Neuron
Synchronized Activity between the Ventral Hippocampus and the Medial Prefrontal Cortex during Anxiety
- Research Article
29
- 10.1139/cjpp-2015-0581
- May 30, 2016
- Canadian Journal of Physiology and Pharmacology
The aim of this study was to examine the effects of a methionine-enriched diet on anxiety-related behavior in rats and to determine the role of the brain oxidative status in these alterations. Adult male Wistar rats were fed from the 30th to 60th postnatal day with standard or methionine-enriched diet (double content comparing with standard diet: 7.7 g/kg). Rats were tested in open field and light-dark tests and afterwards oxidative status in the different brain regions were determined. Hyperhomocysteinemia induced by methionine-enriched diet in this study decreased the number of rearings, as well as the time that these animals spent in the center of the open field, but increased index of thigmotaxy. Oxidative status was selectively altered in the examined regions. Lipid peroxidation was significantly increased in the cortex and nc. caudatus of rats developing hyperhomocysteinemia, but unaltered in the hippocampus and thalamus. Based on the results of this research, it could be concluded that hyperhomocysteinemia induced by methionine nutritional overload increased anxiety-related behavior in rats. These proanxiogenic effects could be, at least in part, a consequence of oxidative stress in the rat brain.
- Research Article
34
- 10.1016/s0006-8993(98)00274-1
- May 1, 1998
- Brain Research
C-type natriuretic peptide exerts effects opposing those of atrial natriuretic peptide on anxiety-related behaviour in rats
- Research Article
30
- 10.1007/s12640-018-9975-2
- Nov 7, 2018
- Neurotoxicity Research
The characteristic feature of Alzheimer's disease (AD) is the deposition of amyloid beta inside the brain mainly consisting of Aβ 40 and 42 aggregates. Soluble aggregates of Aβ 42 are reported to be more toxic and exert their neurotoxicity by the induction of oxidative damage and cognitive deficits such as anxiety-like behavior. These alterations emerge due to the induction of gap junction communication through increased activity and expression of connexins such as connexin43 (Cx43) leading to the release of small neurotoxic molecules. In the present study, single intracerebroventricular (icv) injection of Aβ 42 oligomers (10μl/rat) was used to induce oxidative damage and anxiety-related behavior in rats. Carbenoxolone (Cbx), a gap junction blocker, was tested (20mg/kg body weight, i.p., for 6weeks) against these alterations. Cbx supplementation reversed the Aβ 42 oligomer-induced alterations in the antioxidant defense system. The levels ROS, lipid peroxidation, and protein carbonyls were normalized with Cbx co-treatment leading to the decreased DNA fragmentation and pyknosis in different regions of the rat brain. Cbx induced the anxiolytic behavior and ameliorated the cognitive decline in rats post Aβ 42 oligomer injection. The increased expression of Cx43 post Aβ 42 oligomer injection was also reduced with Cbx supplementation, which might have inhibited the release of small neurotoxic molecules. Our results showed that Cbx prevents the Aβ 42 oligomer-induced oxidative damage and anxiety-like behavior partly by blocking the gap junction communication, which suggests that the therapeutic potential of Cbx may be explored in the progression of AD.
- Research Article
18
- 10.1016/j.cbpc.2020.108701
- Jan 3, 2020
- Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology
4-Nonylphenol and 4-tert-octylphenol induce anxiety-related behaviors through alternation of 5-HT receptors and transporters in the prefrontal cortex